Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 12/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | ESD | P10768 | 1/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740593 | 0.88 | PRKCZ (1.00) | PRKCZMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL16740631 | 0.79 | PRKCZ (1.00) | PRKCZMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL16740663 | 0.78 | PRKCZ (1.00) | PRKCZMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL27792765 | 0.76 | PRKCZ (0.67) | PRKCZMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL16740616 | 0.74 | PRKCZ (0.73) | PRKCZMEN1KMT2AHSP90AA1PDE5A | |
| SCHEMBL16740622 | 0.74 | CA1 (0.63) | PRKCZMEN1KMT2AATMPDE5A | |
| SCHEMBL16740611 | 0.73 | PRKCZ (1.00) | PRKCZMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL9628590 | 0.73 | PRKCZ (1.00) | PRKCZMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL16740614 | 0.71 | PRKCZ (0.69) | PRKCZMEN1KMT2AHSP90AA1ATM | |
| SCHEMBL16740640 | 0.70 | PRKCZ (1.00) | PRKCZMEN1KMT2AHSP90AA1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2015075051-A1 | ALLOSTERIC INHIBITORS OF ATYPICAL PROTEIN KINASES C | UNIVERSITAET DES SAARLANDES (DE) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | PRKCZ 25/4885MEN1 3627/4885KMT2A 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.